Xenon Pharmaceuticals
XENE
81 hedge funds and large institutions have $431M invested in Xenon Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 8 closing their positions.
39% more capital invested
Capital invested by funds: $309M → $431M (+$122M)
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
19% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 21
1% more funds holding
Funds holding: 80 → 81 (+1)
0.25% more ownership
Funds ownership: 79.79% → 80.04% (+0.25%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$4.39M |
| 2 |
BlackRock
New York
|
+$4.1M |
| 3 |
Millennium Management
New York
|
+$3.48M |
| 4 |
Bank of New York Mellon
New York
|
+$2.37M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$910K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$6.64M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.85M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.81M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.57M |
| 5 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
-$1.67M |
XENE Hedge Fund Activity: Q4 2020 in Review
81 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2020, worth a combined $431M — up 39% from $309M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new XENE positions and 8 closed out — a net gain of 2 holders — while 25 added to existing stakes and 21 trimmed.
The largest buyer was Ghost Tree Capital, adding an estimated $4.39M. The largest seller was Boxer Capital, exiting entirely with an estimated $6.64M sold.
- 81 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2020, up from 80 in Q3 2020.
- Funds reported $431M of Xenon Pharmaceuticals stock for Q4 2020, up 39% quarter-over-quarter.
- 10 funds opened new Xenon Pharmaceuticals positions in Q4 2020 and 8 closed out, a net change of +2 holders.
- The largest Xenon Pharmaceuticals buyer in Q4 2020 was Ghost Tree Capital, an estimated $4.39M added.
- The largest Xenon Pharmaceuticals seller in Q4 2020 was Boxer Capital, an estimated $6.64M sold.
Based on aggregated 13F filings for Q4 2020.